Dual inhibition of mTOR pathway and VEGF signalling in neuroendocrine neoplasms: From bench to bedside
详细信息 查看全文
- 作者：Chiara Alessandra Cella ; Saverio Minucci ; Francesca Spada ; Salvatore Galdy ; Mohamed Elgendy ; Paola Simona Ravenda ; Maria Giulia Zampino ; Sabina Murgioni ; Nicola Fazio ; nicola.fazio@ieo.it" class="auth_mail" title="E-mail the corresponding author
- 关键词：Neuroendocrine tumours ; Dual inhibition ; mTOR pathway ; VEGF signalling ; Hypoxia
- 刊名：Cancer Treatment Reviews
- 出版年：2015
- 出版时间：November 2015
- 年：2015
- 卷：41
- 期：9
- 页码：754-760
- 全文大小：453 K
文摘
- •
Clinical trials reported a potential synergistic effect of sunitinib in combination to rapalogs in some advanced cancers.
- •
Several VEGF pathway inhibitors have shown clinical activity in NENs.
- •
Sunitinib exhibits a weak cytotoxic activity due to its inhibitory effect on VEGFR2 signalling.
- •
Inhibition of Akt/mTOR signalling sensitises resistant cancer cells to treatment with sunitinib.
- •
We discuss the role of dual blockade of VEGF and mTOR pathway, focusing on current studies and future perspectives.